Loading
The nonsteroidal mineralocorticoid receptor antagonist that closes the residual DKD risk gap — evidence, potassium management, and combination therapy positioning.
Evidence reviewed & updated: 2026-07 — reflects the latest published trials and guidelines.
Finerenone is the first nonsteroidal mineralocorticoid receptor antagonist approved for diabetic kidney disease. FIDELIO-DKD (NEJM 2020) showed 18% reduction in kidney composite outcomes; FIGARO-DKD (NEJM 2021) showed 13% reduction in CV composite. It works on top of RAS blockade and SGLT2 inhibition, targeting residual inflammation and fibrosis — with a better hyperkalemia profile than older MRAs.
FIDELIO-DKD (Bakris et al., NEJM 2020) randomized 5,734 patients with T2D and CKD (UACR 30-5000 mg/g, eGFR 25-75) to finerenone 10-20mg or placebo, on top of optimized RAS blockade. Primary composite (kidney failure, sustained ≥40% eGFR decline, renal death): 18% relative risk reduction (HR 0.82).
Key secondary outcomes: CV composite reduced 14% (HR 0.86). The albuminuria reduction was significant (~30% at 4 months) and sustained. The benefit appeared early and widened over time.
Safety: hyperkalemia leading to discontinuation was 2.3% (finerenone) vs 0.9% (placebo) — much lower than historical spironolactone rates in this population. No excess gynecomastia (unlike steroidal MRAs).
FIGARO-DKD (Pitt et al., NEJM 2021) randomized 7,437 patients with T2D and milder CKD (UACR 30-300 with eGFR 25-90, or UACR 300-5000 with eGFR >60) — a broader, earlier-stage population. Primary CV composite (CV death, nonfatal MI, nonfatal stroke, HF hospitalization): 13% reduction (HR 0.87).
HF hospitalization reduction was the strongest signal (29% reduction, HR 0.71). New-onset atrial fibrillation also reduced. Kidney outcomes trended favorably but did not reach significance individually — consistent with the earlier-stage population.
The FIDELITY pooled analysis (NEJM 2024) of both trials (13,171 patients) confirmed: 23% reduction in CV composite, 14% reduction in kidney failure/eGFR decline outcomes, and consistent benefit across eGFR/UACR subgroups.
Steroidal MRAs (spironolactone, eplerenone) activate both MR and other steroid receptors — causing gynecomastia, irregular menses, and hyperkalemia — limiting use in CKD. Finerenone is a selective, nonsteroidal MR antagonist with a balanced receptor distribution between kidney and heart.
Mechanism: aldosterone → MR activation → inflammation, fibrosis, and sodium retention in podocytes, tubules, and vasculature. Finerenone blocks this pathway, reducing albuminuria, fibrosis, and vascular stiffness — the 'residual risk' pathway not covered by RAS blockade (aldosterone escape).
Unlike SGLT2i (hemodynamic), finerenone is primarily anti-inflammatory/anti-fibrotic — making the combination mechanistically additive.
Eligibility: only start if serum K+ <4.8 mEq/L (some protocols <5.0). Measure K+ at baseline, 1 month, 4 months, then quarterly; more frequently with dose changes or intercurrent illness.
If K+ rises >5.5 mEq/L: reassess diet (potassium-rich foods), check for medications contributing (trimethoprim, NSAIDs, RAS blockade titration), and consider potassium binders (patiromer, SZC) rather than discontinuation.
K+ >5.5 on repeat → hold finerenone; restart at lower dose when K+ <5.0. K+ >6.0 or with ECG changes → emergency management per hyperkalemia protocols. With structured monitoring (EMR alerts), discontinuation rates can be kept low.
The 'quadruple therapy' era for diabetic CKD: RAS blockade (ACEi/ARB) + SGLT2 inhibitor + GLP-1 RA + finerenone. Each addresses a different pathway; benefits are additive. Finerenone is added for residual albuminuria/CV risk after SGLT2i + RASi optimization.
KDIGO 2022 Diabetes Guideline recommends finerenone for T2D+CKD with albuminuria despite maximally tolerated RASi + SGLT2i. ADA 2024 similar. EMA/FDA approved for T2D+albuminuric CKD.
For practices: the clinical workflow is (1) confirm K+ <4.8, (2) start finerenone 10-20mg, (3) monitor K+ + UACR at 1 and 4 months then quarterly, (4) use potassium binders for moderate hyperkalemia instead of stopping. ZuvFlo's therapy-tracking module automates these monitoring intervals with alerts.
Advertisement
SGLT2 inhibitors (dapagliflozin, empagliflozin) are the most impactful CKD therapy advance in a decade. DAPA-CKD (NEJM 2...
Learn moreThe FLOW trial (Perkovic et al., NEJM 2024) randomized 3,533 CKD patients with T2D to semaglutide 1mg or placebo — stopp...
Learn moreHyperkalemia (K+ >5.0) is a common, dangerous complication of CKD and a major reason patients are taken off life-saving ...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.